Event-Driven Stocks

Coherus Oncology, Inc.

CHRSNasdaq

Healthcare · Biological Products, (No Diagnostic Substances) · DE · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 1 good● 6 warning● 1 severedetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue$42.2M$267.0M$257.2M$211.0M$326.6M$475.8M
Operating income−$181.1M−$111.7M−$203.2M−$256.9M−$263.9M$156.3M
Net income$168.0M$28.5M−$237.9M−$291.8M−$287.1M$132.2M
Total assets$258.3M$448.5M$629.6M$480.8M$679.3M$841.6M
Total liabilities$197.3M$580.5M$823.0M$618.3M$581.6M$560.7M
Equity$61.0M−$132.0M−$193.4M−$137.4M$97.7M$281.0M
EPS (diluted)$1.43$0.25$-2.53$-3.76$-3.81$1.62
Shares out.115.9M112.7M79.6M77.3M72.8M70.6M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
−429.5%
Net margin
398.4%
Return on equity
275.4%
Return on assets
65.0%
Return on capital (ROCE)
−153.6%
Liabilities / assets
76.4%
Debt / equity
3.23×
Book value / share
$0.53
Revenue growth (YoY)
−84.2%
Net income growth (YoY)
489.4%

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Altman Z″ (distress)
-20.15distress
Accruals / assets
118.7%high accruals
Beneish M-Score
1.81elevated
Piotroski F-Score
4/9mixed

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
39
/ 100
Profitability 60Growth 50Catalyst 33Earnings quality 0Financial strength 50

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 1 severe● 6 warning● 1 good
  • Altman Z″ in the distress zone
  • Operating losses (negative operating margin)
  • Revenue declined year-over-year
  • High leverage (liabilities > 70% of assets)
  • Negative operating cash flow
  • High accruals — earnings-quality risk
  • Beneish M-Score elevated — earnings-manipulation screen flag
  • Strong return on equity (>15%)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 202628.1M17.2+1.0%
Apr 30, 202627.8M25.5-0.6%
Apr 15, 202628.0M34.7-0.6%
Mar 31, 202628.1M20.7+0.4%
Mar 13, 202628.0M17.5+1.3%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (1)